Category Archives: Latanoprost

Latanoprost, Minoxidil, Topical Finasteride, Triple Hair

Triple Hair Therapy-07 Phase 3 Clinical Trials Begin

6 Comments

Triple Hair is a Canadian biotechnology company that is developing new topical treatments for men and women who suffer from androgenic alopecia. Its main hair loss product will enter Phase 3 trials in 2026 and contains Minoxidil (5%), Finasteride (0.1%) and Latanoprost (0.03%).

Triple Hair TH07 Phase 3 Clinical Trials Begin

Update: February 27, 2027

The Phase 3 trials for Triple Hair’s Therapy-07 (THO7) will start in Vancouver, British Columbia (Canada) in April 2026. They have started the process of recruiting 420 volunteers for this 24-week trial. Since all three of the key ingredients in TH07 are already FDA approved and well established, I would not be too concerned about side effects. But you should still consult a doctor first if you plan to enroll in this trial.

On the company’s website, they also state that they will conduct another Phase 3 trial in India.

June 20, 2024

Triple Hair
Triple Hair TH07.

Triple Hair: Therapy-07 for Hair Growth

Triple Hair’s main product is a prescription triple combination topical called Therapy-07. It contains minoxidil, finasteride and latanoprost (a prostaglandin F2α analog). It is currently sold via  prescription through Texas-based Pharmacy Solutions.

When I first read about Therapy-07, while it seemed interesting, it did not sound like anything special to me. The reason is because there are now many online companies that sell topical finasteride containing hair loss products that also include minoxidil and other key ingredients such as latanoprost, spironolactone and resveratrol. In addition:

  • A US-based company named Aneira Pharma is working a product that includes latanoprost, minoxidil and various other ingredients.
  • Another US-based company Dermaliq is preparing for Phase clinical trials for its prostaglandin F2α analogue topical hair growth product DLQ01 that is thought to contain latanoprost.
  • A Poland-based company BioReseach Pharma is working on a latanoprost acid based hair loss product.

Phase 3 Clinical Trial Approvals in Europe and Canada

However, today I changed my mind slightly after reader “John Doe” e-mailed me to notify that Triple Hair has just received EMA approval to start phase III clinical trials for its Therapy-07 prescription drug in Europe.

Do note that in June 2023, Triple Hair already received approval to begin phase III clinical trials in Canada. At the time, company CEO Jean-Philippe Gravel said that they were also awaiting similar approvals in the US and Europe. As soon as all approvals are obtained they planned to begin the final trials.

So far, among the many companies selling topical finasteride for hair loss, only Almirall (Spain) has gone through the entire three stage clinical trial process. The expenses to go through three trials for a topical hair loss product is generally not justifiable to investors. Especially with key ingredients such as finasteride and minoxidil.

Therapy-16

Triple Hair also sells an over-the-counter hair loss product called Therapy-16. For men, it is sold via the brand name Rizn. It is a drug-free once a day formula that is made with natural ingredients. They sell a RIZN Hair Density Spray and RIZN Hair Complex pills. The woman’s Therapy-16 Hair Densifying Spray product goes by the brand name Plenty Natural. It contains Japanese knotweed, melatonin and peasprout extracts.

Interestingly, the company claims that these products reduce Prostaglandin D2 (PGD2) levels, which aid hair growth. I discussed the positive impact of decreasing PGD2 on hair growth in several posts in the past. However, I am skeptical about how big an impact natural products can have on scalp PGD2 levels.

Androgenetic Alopecia, Latanoprost, Latanoprost Acid, Psoriasis

BioResearch Pharma BRP-011: Latanoprost Acid for Hair Growth

8 Comments
Bioresearch Pharma BRP-011 Latanoprost Acid
Bioresearch Pharma BRP-011: Latanoprost Acid for Hair Growth.
Latanoprost Eyelash Hair Growth
Latanoprost Eyelash Hair Growth. Source: Nature, July 1998.

In just the past month, I covered two different companies working on a latanoprost based hair loss treatment (Canada-based Triple Hair and US-based Dermaliq). Both companies are almost certain to continue to Phase 3 clinical trials in the near future.

I also covered US-based Aneira Pharma and its latanoprost containing combination hair loss product in 2021. While the company has not updated its website for a few years, its patent application status page has been updated a few times in 2024.

Latanoprost is a prostaglandin F2α analogue eye medication that is meant to be used to treat glaucoma and ocular hypertension. It was approved for medical use in the US in 1996. An unusual side effect of latanoprost is increased and thicker eyelash hair growth. A rarer side effects is eyelash hair darkening (see image above from here).

BioResearch Pharma BRP-011: Latanoprost Acid for Hair Growth

Now comes news of BioResearch Pharma (Poland) working on a latanoprost acid based hair loss product called BRP-011. Thanks to “Ben” for posting a link to a very encouraging recent Polish magazine interview with CEO Lukasz Zybaczyński. This company was originally mentioned by “John Doe” in a comment earlier this year, and he also e-mailed me the above interview link.

According to the BRP-011 product page:

  • Latanoprost’s high skin penetration rate has raised concerns about potential systemic adverse side effects.
  • Consequently, latanoprost acid (an active metabolite of latanoprost) has emerged as an alternative option.
  • Latanoprost acid was initially dismissed as a potential topical treatment due to its low bioavailability.
  • However, BioResearch Pharma (BRP)’s chief scientific officer and co-founder Dr. Katarzyna Koziak has shown latanoprost acid to promote hair growth in a clinical setting involving indiviuals with androgenetic alopecia.

Note that BRP is only focusing on treating two conditions: androgenetic alopecia and psoriasis (via drug candidate BRP-007).

Commercialization in 2027

In the new CEO interview, the most interesting points relate to a very optimistic timeline forecast due to the nature of BRP’s products. Key quotes in bullet points (wording slightly modified by me):

  • BioResearch Pharma does not want to discover a new medicine and prove its safety, which usually takes years. The company intend to use an existing active substance in a new mechanism of action in a new route of administration. Regulatory agencies allow the registration of a medicine in a new therapeutic indication, using publications and data that are not the property of the applicant.
  • In the case of a new chemical molecule, the initial stages of the drug development process related to production and pre-clinical evaluation take around 5 to 7 years. In BRP’s repositioning process, they shorten this period to a year, relying on the past experiences of other pharmaceutical companies and patients. This method confirms safety standards.
  • In total, an up to 9 year process will be shortened to 2-3 years by BRP. i.e., much faster clinical trials.
  • In 2025, the company will begin the registration process.
  • The CEO anticipates commercialization after completing Phase I of clinical trials. This should happen by the end of 2026 for both projects (androgenetic alopecia and psoriasis). So commercialization in 2027.

The latter part of the interview relates to fundraising and a pending IPO.